SAVE MONEY ON TRAVEL DEALS

Project investigator Jay Ma of the Oklahoma University Health Sciences Center and Dean A. McGee Eye Institute said when the researchers delivered the new compound to cells using nanoparticle technology, the treatment stopped leakage, blocked inflammation and kept unwanted blood vessels from growing in research models.

"There is no good treatment for retinopathy, which is why we are so excited about this work", Ma said in a statement. "This opens an entirely new area for pharmaceutical companies to target."

The discovery of the compound's function in inflammation and blood vessel formation related to eye disease means scientists can develop new therapies -- such as eye drops -- to stop diabetic retinopathy, Ma said.

Diabetic retinopathy, a disease that affects as many as 5 million Americans, is caused by changes in blood vessels of the retina, the light-sensitive tissue at the back of the eye. In some people with diabetic retinopathy, blood vessels may swell and leak fluid. In others, abnormal new blood vessels grow on the surface of the retina.

 BREAKING STORIES

Chemo gives parrot additional 9 months

Older non-smokers gain most by smoking ban

Disease rates for Asian-Americans differ

Most older Canadians use 5 medications/day

Omega 3 may curb colon polyps

Obesity, passive smoke: Babies at risk

Chemical may protect MD patients' hearts

How healthcare reform affects consumers

Cloves: The natural food anti-oxidant

Doctors want 10 new antibiotics by 2020

Scientist urges better cancer cell tests

Genes don't help predict breast cancer

Workers get flu shot if co-workers do

Anticipation may be a factor in diabetes

New risk score better predicts heart risk

BP may need to be just right for diabetics

Heart abnormalities found in WTC workers

Red Sox player's brain surgery successful

Regular mealtimes help kids with asthma

Falls, accidents cause most brain injuries